Companies: 10,795·Total market cap: $144.5T
Zymeworks Inc.

Zymeworks Inc.

ZYMENASDAQHealthcare● Active
$23.93
$-0.11(-0.46%)
Market Cap$1.8B
P/E Ratio
52W High$29.75
52W Low$11.51
Overview

Zymeworks Inc. (ZYME) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · ZYME · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-1.37zyme eps ttm · zyme earnings per shareEarnings history
PE Ratio (TTM)zyme pe ratio ttm · zyme price to earningsPE Ratio deep dive
Revenue (TTM)$81.3Mzyme revenue ttm · zyme annual revenueFull revenue history
Dividend YieldNo Dividenddoes zyme pay dividends · zyme dividend yieldDividend history
Shares Outstanding75.3Mzyme shares outstanding · zyme floatShares outstanding history
Next EarningsAug 6, 2026Est.zyme earnings date · zyme next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$106.0M▲ +38.87% YoY
202320242025
zymeworks inc. revenue · zyme revenue 2025
FY 2025Net Income-$81.1M▲ +33.88% YoY
202320242025
zymeworks inc. net income · zyme profit 2025
FY 2025EPS$-1.08▲ +33.33% YoY
202320242025
zyme eps · zymeworks inc. earnings per share 2025
TTM:Revenue: $81.3MNet Income: -$102.7MEPS: $-1.37View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy20 analystsis zyme a buy · zyme analyst rating
Strong Buy
0
Buy
18
Hold
2
Sell
0
Strong Sell
0
12-Month Price Target
$33.00Low
$23.93Current
$41.75Avg Target74.47% upside
$48.00High
zyme price target · zyme 12 month forecast

Total: 20 · Buy rate: 90.0%

The ZYME analyst consensus is Buy, based on ratings from 20 Wall Street analysts over the past 3 months. The average 12-month price target is $41.75, representing +74.47% upside from the current price of $23.93.

Stock Performance

Full History
1D-0.46%
1W-1.60%
1M+0.17%
3M-0.62%
YTD-9.12%
1Y+92.21%
5Y-32.61%

About Zymeworks Inc.

CEOKenneth H. Galbraith
IPO DateApr 28, 2017
Employees299
CountryCA

Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline f…

what is zymeworks inc. · zyme stock overview · zymeworks inc. company profile · who is zymeworks inc. ceo · zyme NASDAQ · zymeworks inc. headquarters · zymeworks inc. business segments

About Stock Overview & Key Data

Zymeworks Inc. (ZYME) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Apr 28, 2017. As of the latest trading session, ZYME stock price is $23.93, with a market capitalization of $1.8B. The stock has returned +92.21% over the past 12 months and -9.12% year-to-date.

According to 20 Wall Street analysts, the consensus rating for Zymeworks Inc. stock is Buy, with an average 12-month price target of $41.75. In fiscal year 2025, Zymeworks Inc. reported revenue of $106.0M and net income of -$81.1M. For detailed data — including Zymeworks Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Zymeworks Inc. (ZYME) stock price is $23.93. The stock is traded on NASDAQ under the ticker symbol ZYME. The 52-week range is $11.51 – $29.75.

ZYME stock priceZYME quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice